Multifunctional Nanoprobe for the Delivery of Therapeutic siRNA and Real-Time Molecular Imaging of Parkinson's Disease Biomarkers
Parkinson's disease (PD) has been recently associated with the excessive expression of matrix metalloproteinase 3 (MMP3). One of the major challenges in treating PD is to effectively detect and inhibit the early MMP3 activities to relieve the neural stress and inflammation responses. Previously, numerous upconversion nanoparticle (UCNP)-based nanoprobes have been designed for the detection of biomarkers in neurodegenerative diseases. To further improve the performance of the conventional nanoprobes, we introduced novel reporting units and integrated the therapeutic reagents to fabricate a theragnostic platform for PD and other neurodegenerative diseases. Here, we designed a multifunctional UCNP/aggregation-induced emission luminogen (AIEgen)-based nanoprobe to effectively detect the time-lapse MMP3 activities in the inflammatory catecholaminergic SH-SY5Y cells and simultaneously deliver the MMP3-siRNA into the stressed catecholaminergic SH-SY5Y cells, inhibiting the MMP3-induced inflammatory neural responses. The unique features of our UCNP/AIEgen-based nanoprobe platform shed light on the development of a novel theragnostic probe for the early diagnosis and cure of neurodegenerative diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
ACS applied materials & interfaces - 13(2021), 10 vom: 17. März, Seite 11609-11620 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Rui [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.07.2021 Date Revised 20.07.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acsami.0c22112 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322410762 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322410762 | ||
003 | DE-627 | ||
005 | 20231225182001.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acsami.0c22112 |2 doi | |
028 | 5 | 2 | |a pubmed24n1074.xml |
035 | |a (DE-627)NLM322410762 | ||
035 | |a (NLM)33683858 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Rui |e verfasserin |4 aut | |
245 | 1 | 0 | |a Multifunctional Nanoprobe for the Delivery of Therapeutic siRNA and Real-Time Molecular Imaging of Parkinson's Disease Biomarkers |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.07.2021 | ||
500 | |a Date Revised 20.07.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Parkinson's disease (PD) has been recently associated with the excessive expression of matrix metalloproteinase 3 (MMP3). One of the major challenges in treating PD is to effectively detect and inhibit the early MMP3 activities to relieve the neural stress and inflammation responses. Previously, numerous upconversion nanoparticle (UCNP)-based nanoprobes have been designed for the detection of biomarkers in neurodegenerative diseases. To further improve the performance of the conventional nanoprobes, we introduced novel reporting units and integrated the therapeutic reagents to fabricate a theragnostic platform for PD and other neurodegenerative diseases. Here, we designed a multifunctional UCNP/aggregation-induced emission luminogen (AIEgen)-based nanoprobe to effectively detect the time-lapse MMP3 activities in the inflammatory catecholaminergic SH-SY5Y cells and simultaneously deliver the MMP3-siRNA into the stressed catecholaminergic SH-SY5Y cells, inhibiting the MMP3-induced inflammatory neural responses. The unique features of our UCNP/AIEgen-based nanoprobe platform shed light on the development of a novel theragnostic probe for the early diagnosis and cure of neurodegenerative diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Parkinson’s disease | |
650 | 4 | |a aggregation-induced emission | |
650 | 4 | |a biomarker-triggered nanoprobe | |
650 | 4 | |a metalloproteinase 3 | |
650 | 4 | |a upconversion nanoparticles | |
650 | 7 | |a Peptides |2 NLM | |
650 | 7 | |a RNA, Small Interfering |2 NLM | |
650 | 7 | |a Matrix Metalloproteinase 3 |2 NLM | |
650 | 7 | |a EC 3.4.24.17 |2 NLM | |
700 | 1 | |a Li, Yi |e verfasserin |4 aut | |
700 | 1 | |a Mu, Mingdao |e verfasserin |4 aut | |
700 | 1 | |a Yang, Boguang |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xiaoyu |e verfasserin |4 aut | |
700 | 1 | |a Lee, Wayne Yuk Wai |e verfasserin |4 aut | |
700 | 1 | |a Ke, Ya |e verfasserin |4 aut | |
700 | 1 | |a Yung, Wing Ho |e verfasserin |4 aut | |
700 | 1 | |a Tang, Ben Zhong |e verfasserin |4 aut | |
700 | 1 | |a Bian, Liming |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ACS applied materials & interfaces |d 2009 |g 13(2021), 10 vom: 17. März, Seite 11609-11620 |w (DE-627)NLM194100049 |x 1944-8252 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2021 |g number:10 |g day:17 |g month:03 |g pages:11609-11620 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsami.0c22112 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2021 |e 10 |b 17 |c 03 |h 11609-11620 |